Notícias e Atividades da Silence Therapeutics

Silence Therapeutics é uma empresa listada sob o símbolo SLN (GB).

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Silence Therapeutics

• Craig Tooman, President and Chief Executive Officer
• Ian Ross, Non-Executive Chairman of the Board
• Dave Lemus, Non-Executive Director

Recentes movimentos de executivos em Silence Therapeutics

• Gianine Esposito, ingressou na Companhia como Chief Human Resources Officer  (Notícia publicada em 18 de agosto de 2024).

Criar um alerta
para seguir os movimentos de executivos da Silence Therapeutics.

Silence Therapeutics possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Silence Therapeutics

• Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
• Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
• Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
• Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
• Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
• Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
• Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
• Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
• Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
• Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
• View more press releases Close

Redes sociais sobre Silence Therapeutics

• Silence Therapeutics na Wikipedia, Google News e Yahoo Finance
• Silence Therapeutics na LinkedIn, Twitter e YouTube